BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its ...
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout ...
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on BridgeBio Pharma, with a price target of $102.00.
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
According to TipRanks.com, Fischbeck is a 3-star analyst with an average return of 2.4% and a 57.2% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Ardent Health ...
RareLabs, a division of AlphaRose Therapeutics, named Rob Freishtat, MD as CEO. Charles Hirner joined NuvemRx as SVP of ...
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
Adds Pfizer statement. BridgeBio (BBIO) fell 1.3% after originally gaining 11% as a court filing disclosed a settlement in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results